---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-041200"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2024-03-29T23:59:59+00:00"
generated_at: "2026-06-04T05:18:08.156927+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Iovance Biotherapeutics director McPeak to retire; interim CEO Vogt nominated to board

## Summary
- Director Merrill A. McPeak to retire and not stand for re-election at June 2024 annual meeting.
- Frederick G. Vogt, Interim CEO and General Counsel, nominated to fill the vacancy.
- Board unanimously adopted Fourth Amended and Restated Bylaws redefining 'Acting in Concert'.
- McPeak's retirement is not due to any disagreement with the Company.

## SEC filing metadata
- accession: 0001104659-24-041200
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2024-03-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465924041200/0001104659-24-041200-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465924041200/tm2410183d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-041200
- JSON: https://secwatch.observer/filing/0001104659-24-041200.json
- Plain text: https://secwatch.observer/filing/0001104659-24-041200.txt

## Key facts
- Executive change
  Frederick G. Vogt was appointed as Director at IOVANCE BIOTHERAPEUTICS, INC..
  - Action: nominated to stand for election
  - Role: Director
  source text: Frederick G. Vogt, Ph.D., J.D., the Company’s Interim Chief Executive Officer and President, and General Counsel, be nominated to stand for election to the Board at the Annual Meeting
  evidence_url: https://www.sec.gov/Archives/edgar/data/1425205/000110465924041200/0001104659-24-041200-index.htm
- Executive change
  Merrill A. McPeak retired as Director at IOVANCE BIOTHERAPEUTICS, INC..
  - Action: retired
  - Role: Director
  source text: General (Ret.) Merrill A. McPeak, a member of the Board of Directors (the “ Board ”) of Iovance Biotherapeutics, Inc. (the “ Company ”), provided notice to the Board that he will retire and not be standing for re-election to the Board at the Company’s annual meeting
  evidence_url: https://www.sec.gov/Archives/edgar/data/1425205/000110465924041200/0001104659-24-041200-index.htm
- Governance Changes
  IOVANCE BIOTHERAPEUTICS, INC.: Amended and restated bylaws to modify the definition of 'Acting in Concert' (effective 2024-03-28).
  - Change: bylaw amendment
  - Effective: 2024-03-28
  source text: On March 28, 2024, the Board unanimously adopted the Company’s Fourth Amended and Restated Bylaws
  evidence_url: https://www.sec.gov/Archives/edgar/data/1425205/000110465924041200/0001104659-24-041200-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.